Another PML case associated with Raptiva
Executive Summary
A second case of progressive multifocal leukoencephalopathy associated with Raptiva (efalizumab) prompts Genentech to issue another Dear Healthcare Provider letter to dermatologists and neurologists. The current case caused the death of a 73-year old woman treated for four years with Raptiva for chronic plaque psoriasis, and follows a similar case in October. Genentech says it believes the drug likely increases the risk of PML and that prolonged exposure to Raptiva and older age may further increase this risk. The drug's labeling was updated in October and FDA has asked the firm to submit a Risk Evaluation and Mitigation Strategy (1"The Pink Sheet" DAILY, Oct. 17, 2008)
You may also be interested in...
Raptiva PML Case Brings Another REMS
FDA wants black-box warning, new safety plan for psoriasis drug.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.